Miles Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Miles Capital’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,771	Closed	-$228K	–	179
2019 Q2	$228K	Buy	+2,771	New	+$197K	0.19%	147

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Miles Capital's ANIP Position: Q3 2019 in Review

Miles Capital sold out of ANI Pharmaceuticals (ANIP) in Q3 2019, closing a stake of 2,771 shares — an estimated $228K sold.

Miles Capital first reported a position in ANIP in Q2 2019 and held it in 1 quarter. The position peaked at $228K in Q2 2019. 190 funds tracked by Wall St. Rank hold ANIP as of Q3 2019.

Miles Capital reported no remaining ANI Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Miles Capital sold 2,771 ANI Pharmaceuticals shares in Q3 2019, an estimated $228K.
Miles Capital first reported a position in ANI Pharmaceuticals in Q2 2019 and held it in 1 quarter.
Miles Capital's ANI Pharmaceuticals position peaked at $228K in Q2 2019.
190 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2019.

Based on Miles Capital's 13F filing for Q3 2019, filed 7 Nov 2019.